Skip to main content

Table 3 Asthma disease characteristics by cohort at Baseline Visit (Screening or Baseline for PC20)

From: Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study

Cohorts Healthy Mild Moderate Severe P-value***
N 30 52 55 51  
Pre-BD FEV1 (L) 3.98 (0.81) * 3.35 (0.81) 2.39 (0.62) 2.10 (0.71) <0.0001
Pre-BD FEV1 (% predicted normal) 103.3 (13.4) 92.7 (14.3) 73.6 (10.4) 65.4 (12.7) <0.0001
Post-BD FEV1 (L) 4.10 (0.84) 3.61 (0.87) 2.67 (0.66) 2.43 (0.81) <0.0001
Post-BD FEV1 (% predicted normal) 106.2 (13.7) 101.4 (14.0) 82.7 (10.2) 75.7 (15.4) <0.0001
Pre-BD FEV/FVC ratio 0.83 (0.06) 0.77 (0.08) 0.66 (0.09) 0.61 (0.09) <0.0001
Post-BD FVC (% predicted normal) 103.8 (15.9) 105.0 (15.5) 96.4 (11.4) 94.0 (15.1) 0.0004
BDR (%) 2.9 (4.1) 8.5 (8.3) 15.2 (10.3) 18.3 (14.5) 0.0016
BDR (mL) 114.8 (140.6) 265.1 (231.7) 335.2 (234.3) 355.7 (270.6) 0.45
PC20 methacholine (mg/mL) NA 1.68 (+10.85/-0.26)** 0.93 (+6.49/-0.13)** 0.63 (+2.62/-0.15)** 0.034
ACQ7 NA 0.84 (0.69) 1.33 (0.71) 1.92 (1.01) <0.0001
Controlled ACQ <0.75 (N, %) NA 29 (56 %) 10 (18 %) 4 (8 %)  
Partially controlled ACQ 0.75-1.5 (N, %) NA 13 (25 %) 24 (44 %) 16 (31 %) <0.0001
Uncontrolled ACQ ≥ 1.5 (N, %) NA 10 (19 %) 21 (38 %) 31 (61 %)  
AQLQ NA 5.86 (0.93) 5.68 (1.11) 5.09 (1.28) 0.0016
  1. *Mean (standard deviation) reported by cohort, unless otherwise indicated ** Geometric mean (asymmetric standard deviation) *** p-value (ANOVA F-test, or Fisher’s exact test when N, % reported) for differences across severity cohorts, excluding healthy control cohort (based on log-transformed data when geometric means reported)